Debt-to-equity of Serina Therapeutics, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Serina Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Serina Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 500%.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Serina Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 500% +602% 30 Sep 2025
Q2 2025 -415% -351% -554% 30 Jun 2025
Q1 2025 -215% -147% -217% 31 Mar 2025
Q4 2024 -206% -142% -221% 31 Dec 2024
Q3 2024 -102% -28% -38% 30 Sep 2024
Q2 2024 -63% +31% +33% 30 Jun 2024
Q1 2024 -68% +16% +20% 31 Mar 2024
Q4 2023 -64% +23% +27% 31 Dec 2023
Q3 2023 -74% +46% +39% 30 Sep 2023
Q2 2023 -94% +29% +24% 30 Jun 2023
Q1 2023 -84% +42% +33% 31 Mar 2023
Q4 2022 -87% +44% +34% 31 Dec 2022
Q3 2022 -121% +22% +15% 30 Sep 2022
Q2 2022 -124% +38% +24% 30 Jun 2022
Q1 2022 -126% +67% +35% 31 Mar 2022
Q4 2021 -132% +116% +47% 31 Dec 2021
Q3 2021 -142% +402% +74% 30 Sep 2021
Q2 2021 -162% -767% -127% 30 Jun 2021
Q1 2021 -193% -324% -248% 31 Mar 2021
Q4 2020 -248% -306% -524% 31 Dec 2020
Q3 2020 -544% -583% -1500% 30 Sep 2020
Q2 2020 605% 30 Jun 2020
Q1 2020 130% 31 Mar 2020
Q4 2019 58% 31 Dec 2019
Q3 2019 39% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.